Making Asahi C&I Co., Ltd. a consolidated subsidiary
First written in FY2019-Q1. 2 of 4 entries say "Restated". Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023Changed the name of 株式会社アサヒ・シーアンドアイ to 株式会社CMCエクスメディカAnnual report
「株式会社アサヒ・シーアンドアイ changed its name to 株式会社CMCエクスメディカ on 1 October 2022.」
The name change of the consolidated subsidiary responsible for the medical and pharmaceutical marketing business is disclosed. - FY2019-Q3RestatedAnnual report
「In addition, from the first quarter of the current fiscal year, 株式会社アサヒ・シーアンドアイ has been included in the scope of consolidation as its importance increased.」
The company has reconfirmed that アサヒ・シーアンドアイ has been a consolidated subsidiary since the first quarter. - FY2019-Q2RestatedAnnual report
「From the first quarter of the current fiscal year, 株式会社アサヒ・シーアンドアイ has been included in the scope of consolidation as its importance increased.」
The company has reconfirmed that 株式会社アサヒ・シーアンドアイ, which operates the medical and pharmaceutical marketing business, has been a consolidated subsidiary since the first quarter. - FY2019-Q1First statedAnnual report
「As a result, 株式会社アサヒ・シーアンドアイ, which operates the group's medical and pharmaceutical marketing business, became a consolidated subsidiary as its importance to the group increased. The medical and pharmaceutical marketing business involves planning and producing content for healthcare professionals and consumers, including MR training support, support for medical exhibitions, and clinical trial document-related solutions.」
As the importance of 株式会社アサヒ・シーアンドアイ, which operates the medical and pharmaceutical marketing business, increased, it has been included in the scope of consolidation from the first quarter of the current fiscal year.